|
|
|
|
Thursday, February 13, 2020
TherapeuticsMD Inc. (TXMD)
Pre-Q4 Overview: Adjusting Our Earnings Estimates
(current) TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD’ and BocaGreenMD’ brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Overview. Prior to fourth quarter earnings reporting, we are updating our estimates and wanted to convey our latest thoughts on the company. In this report, we disclose our estimates for each product, having previously reported total revenue numbers. Our investment thesis remains unchanged as we see healthy volume growth and believe all the products are well positioned in the women’s health space.
Our fourth-quarter estimates for the three commercial products. The company transitioned to commercial state following launches of three products (Imvexxy, Bijuva and Annovera) in 2018-2019. The total revenues from these products reached $10.9 mm in the 9-months of 2019; ($9.9 mm from Imvexxy, $0.6 mm from Bijuva, and $0.4mm from Annovera). We are forecasting $6.7 mm sales for Imvexxy, $1.1 mm for Bijuva and…
Get the full report on Channelchek desktop.
This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.